Abstract: The present invention relates to Saccharomyces boulardii yeast cells, for use in the prevention or treatment of mood disorders, in a person.

Abstract: A pharmaceutical composition for promoting osteoblastogenesis, in particular a yeast cell derived product for use for promoting osteoblastogenesis in an individual. The yeast cell-derived product may be derived from yeast cells of the genus Saccharomyces and from yeast cells of the species Saccharomyces boulardii.

Abstract: The present invention relates to a pharmaceutical oral formulation for use in the administration of at least two bacteria derived from fecal microbiota to mammals for the treatment and/or prevention of dysbiosis and associated pathologies. The pharmaceutical oral formulation is encapsulated mixture of at least two bacteria derived from fecal microbiota wherein the capsules are coated in a pH responsive polymer composition comprising: a. 50-70% poly(methyl acrylate-co-methyl methacrylate-co-methacrylic acid) 7:3:1 by weight of dry polymer, b. 10-30% poly(methacrylic acid-co-ethyl acrylate) 1:1 by weight of dry polymer, c. at least one fatty acid mono-, di- or tri-glyceride ester, or mixtures thereof, d. at least one plasticizer, e. at least one non-ionic emulsifier. The pharmaceutical oral formulation is especially designed to be delivered principally in the ileum and colon and to maintain the sample bacterial viability and diversity.

Abstract: The present invention relates to a compound of the following formula (I): or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment of obsessions and/or compulsions in an individual.

Abstract: The present invention relates to a compound of the following formula (I): or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment of autism spectrum disorders (ASD).

Abstract: The present invention relates to a dietary supplement or pharmaceutical composition, comprising lyophylized Saccharomyces boulardii as an active ingredient and as sole probiotic, optionally in association with a pharmaceutically acceptable vehicle, wherein the composition is in a closed vial a having a first airtight compartment comprising lyophilized S. boulardii powder, and a second compartment comprising a solution, wherein the first and second compartment can be brought in airtight communication with one another to yield a suspension of S. boulardii to be administered to an individual upon opening of the vial.

Abstract: The present invention relates to a compound of the following formula (I): or a pharmaceutically acceptable salt thereof, to be used in the prevention or treatment of light-induced damage and/or a degeneration of the retina in a patient.

Abstract: The present invention relates to a compound of the following formula (I): or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment of peripheral neuropathies.

Abstract: The present invention relates to a pharmaceutical composition comprising as active substances: at least one compound of the following general formula (I): and at least one inhibitor of type 2 cyclooxygenase (COX-2), notably for use in the prevention or treatment of pain.

Abstract: The present invention relates to a pharmaceutical composition comprising as active substances: at least one compound of the following general formula (I): and at least one compound of the following general formula (V): especially for its use in the prevention or treatment of pain.

Abstract: The present invention relates to the use of at least one compound of formula (I) below: or at least one of the pharmaceutically acceptable salts thereof, for the preparation of a medicament intended for the prevention or for the treatment of cerebral edemas.

Abstract: This invention relates to the use of at least one compound of the following formula (I): or its pharmaceutically acceptable salts, for the preparation of a medicinal compound having neuroprotective activity intended to prevent or treat neurone deteriorations.

Abstract: The invention relates to a method of preparation of fluoroquinolones of formula (I) from compounds of formula (II): in which R1, R2, R3, R4, R5, R6, R7, and X are as defined in Claim 1.

Abstract: The invention relates to the use of L-citrulline (I) or of one of its pharmaceutically acceptable salts in the preparation of a drug for the treatment of states or undernutrition as linked to a lowering of protein synthesis within the framework of pathologies which do not result from an intestinal insufficiency.

Abstract: The present invention relates to a method of treating or preventing weight loss of patients with inflammatory bowel diseases comprising administering to said patients an effective amount of Saccharomyces boulardii.

Abstract: The invention relates to a process for the preparation of stiripentol particles having a defined particle size distribution.

Abstract: The present invention relates to the use of at least one compound of formula (I) below: or of its pharmaceutically acceptable salts, in the preparation of a medicament for the prevention or treatment of cerebral oedemas.

Abstract: The present invention relates to the use of L-citrulline (I) for the preparation of a medicament intended for the treatment of pathologies linked to an intestinal insufficiency.